Primary CNS Lymphoma: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Primary CNS lymphoma (PCNSL) is a rare extranodal non-Hodgkin lymphoma arising within and confined at diagnosis to the brain, eyes (vitreoretinal lymphoma), spinal cord, or leptomeninges, without evidence of systemic lymphomatous disease. Over 90% of PCNSL in immunocompetent patients are diffuse large B-cell lymphoma (DLBCL), specifically the activated B-cell (ABC) subtype driven by MYD88 L265P and CD79B mutations. In immunosuppressed patients, PCNSL is EBV-positive DLBCL. PCNSL accounts for approximately 3% of all primary brain tumors and 2-3% of all extranodal lymphomas. The median age at diagnosis in immunocompetent patients is 65-70 years. It is extremely radiosensitive and chemosensitive but carries a high relapse rate without consolidation. Treatment planning requires specialist multidisciplinary expertise. Primary CNS Lymphoma: Causes, Symptoms, Diagnosis and Treatment is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Primary CNS Lymphoma: Causes, Symptoms, Diagnosis and Treatment to help patients understand the condition, its causes, symptoms, and available treatment options.

Immunosuppression is the dominant risk factor for PCNSL: HIV/AIDS patients have a 1,000-fold increased risk, though incidence has fallen dramatically with effective antiretroviral therapy; solid organ transplant recipients receiving calcineurin inhibitors; primary immunodeficiency disorders (Wiskott-Aldrich syndrome, common variable immunodeficiency). EBV drives PCNSL in immunosuppressed patients by enabling B-cell immortalization in an immune-privileged site. In immunocompetent patients over age 60, the rising incidence of sporadic PCNSL reflects age-related immune senescence. The CNS blood-brain barrier limits normal immune surveillance, allowing malignant B-cells to evade systemic immune clearance. MYD88 L265P mutation (present in approximately 80% of PCNSL) and CD79B mutations activate NF-kB signaling and BCR signaling respectively, promoting B-cell survival.

Focal neurological deficits occur in approximately 60% of patients — contralateral hemiparesis, aphasia, and hemisensory deficits reflecting white matter infiltration. Cognitive decline and personality changes are particularly characteristic, occurring in 40-50% of cases and often leading to initial misdiagnosis as dementia or psychiatric illness in elderly patients. Seizures occur in approximately 15% of patients. Raised intracranial pressure causes headache, nausea, and papilledema. Ocular involvement (vitreoretinal lymphoma, uveal infiltration) produces floaters, blurred vision, and photophobia in approximately 20% of cases; slit-lamp examination is mandatory in all suspected PCNSL. Leptomeningeal disease causes spinal pain, radiculopathy, and cauda equina symptoms. B symptoms (fever, night sweats, weight loss) are uncommon in PCNSL.

MRI brain with gadolinium shows characteristic homogeneously contrast-enhancing periventricular white matter lesions — typically crossing the corpus callosum — with surrounding T2/FLAIR signal change. Importantly, corticosteroids must be withheld before stereotactic brain biopsy, as they cause rapid lymphoma lysis and render up to 40% of biopsies non-diagnostic. Stereotactic biopsy confirms histology. CSF cytology and flow cytometry detect leptomeningeal disease in approximately 20-25%. Slit-lamp ophthalmology assesses vitreoretinal involvement. PET-CT or CT thorax, abdomen, pelvis excludes systemic lymphoma and confirms the primary CNS designation. HIV serology and HTLV-1 testing are standard. MYD88 L265P testing on CSF or vitreous fluid aids diagnosis in cases where biopsy is contraindicated.

High-dose methotrexate (HD-MTX) at 3.5-8 g/m2 every 2 weeks is the cornerstone of PCNSL treatment, achieving CNS concentrations sufficient for antilymphoma activity by temporarily disrupting the blood-brain barrier. The IELSG32 randomized trial established MATRix — HD-MTX (3.5 g/m2) plus cytarabine, thiotepa, and rituximab (anti-CD20) every 3 weeks for 4 cycles — as the preferred induction regimen, achieving complete remission in approximately 49% versus 23% with HD-MTX plus rituximab alone. Consolidation in eligible patients under age 65: high-dose chemotherapy (thiotepa-BCNU or BEAM) with autologous stem cell rescue (ASCR) offers durable remissions without whole-brain radiation. Whole-brain radiotherapy (WBRT, 23.4-36 Gy) is reserved for elderly or frail patients ineligible for intensive chemotherapy, at the cost of late neurotoxicity in 20-50%. Rituximab maintenance reduces relapse rates. Relapsed disease: ibrutinib (BTK inhibitor), lenalidomide, PD-1 inhibitors in clinical trials.

Prognosis for primary CNS lymphoma (PCNSL) has improved substantially with high-dose methotrexate-based regimens but remains inferior to systemic DLBCL. Young fit patients under age 65 receiving MATRix induction followed by autologous stem cell rescue (ASCR) consolidation achieve median OS of approximately 4-6 years and 3-year PFS of approximately 50-55% (IELSG32 trial). Elderly patients over age 65 or those receiving WBRT consolidation have median OS of approximately 2-4 years but carry substantial risk of delayed neurotoxicity manifesting as radiation-induced leukoencephalopathy in 20-50%, which significantly impairs quality of life. Complete remission after induction therapy is the strongest predictor of long-term survival: patients achieving CR have 5-year OS of approximately 50-60% compared to 10-20% for partial responders. The IELSG prognostic score (incorporating age, ECOG performance status, LDH, CSF protein, and deep brain structure involvement) stratifies into low-risk (5-year OS greater than 80%), intermediate (approximately 50%), and high-risk (less than 15%). HIV-associated PCNSL treated with HD-MTX plus ART achieves median OS of approximately 12-18 months. Relapsed PCNSL carries a median OS of 2-6 months without effective salvage; ibrutinib achieves partial response in approximately 50% of relapsed cases. Long-term survivors require regular neuropsychological assessment, brain MRI every 6 months for 2 years then annually, and endocrine evaluation for hypothalamic-pituitary dysfunction following WBRT — cognitive decline and gait disturbance may emerge years after treatment.

Prevention of HIV-associated PCNSL relies on universal HIV testing, early antiretroviral therapy (ART) initiation to restore immune function (CD4 count above 200 cells/µL), and HIV pre-exposure prophylaxis (PrEP) in high-risk individuals. Effective ART has reduced PCNSL incidence in HIV-positive populations by approximately 90%. For organ transplant recipients, the lowest effective immunosuppressive regimen reduces lymphoproliferative disorder risk — EBV serology matching of donor and recipient and regular EBV viral load monitoring in the post-transplant period enable early detection of post-transplant lymphoproliferative disease before CNS involvement. There is no established primary prevention for sporadic PCNSL in immunocompetent elderly patients, as the underlying immunosenescence is not currently modifiable. Research into targeted prevention strategies for MYD88 L265P-driven lymphomagenesis is ongoing.

Seek urgent neurological evaluation for: progressive cognitive decline or personality change in an older adult (especially combined with any focal neurological deficit); new focal neurological deficits (hemiparesis, aphasia, visual field loss) without a vascular explanation; floaters, blurred vision, or uveitis-like symptoms that do not respond to standard treatment — vitreoretinal lymphoma is frequently misdiagnosed as uveitis; new onset seizures in an older adult; or any individual with HIV, transplant-related immunosuppression, or other immune compromise who develops new neurological symptoms. PCNSL can be rapidly fatal without treatment — early specialist evaluation, including emergency brain MRI, is essential. Do not start corticosteroids before biopsy is obtained unless herniation is imminent.